Post by StockHorizon Nov 25, 2024 10:12am
$OMER is rallying on FDA-related optimism, driven by advancements in treatment devices. $MYNZ, with its cutting-edge cancer diagnostic capabilities, is positioned to benefit from the same sector buzz.
...more